Sign In
Buy PRTK
$2.23
+0 (+0%)
At Close: Dec 19, 2023
Paratek Secures BARDA Funding To Develop Nuzyra Antibiotic For Pulmonary Anthrax
08:24am, Tuesday, 28'th Sep 2021
The Biomedical Advanced Research and Development Authority (BARDA) has awarded an option under Paratek Pharmaceuticals Inc's (NASDAQ: PRTK) Project BioShield contract. Related Link: Paratek's
-- Additional ~$19M Funding for Expanded Anthrax PEP Development Program
Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2021
04:05pm, Thursday, 23'rd Sep 2021
Key highlights include real-world health outcomes data for pneumonia and skin infections, data on in vitro activity against B. anthracis, and real-world experience for nontuberculous mycobacterial inf
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Wednesday, 01'st Sep 2021
BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav
Paratek's (PRTK) Nuzyra Gets FDA's Orphan Drug Tag for NTM
01:48pm, Thursday, 19'th Aug 2021
The FDA bestows an Orphan Drug designation to Paratek's (PRTK) marketed drug Nuzyra for the treatment of infections caused by Nontuberculous Mycobacteria.
Paratek's Antibiotic Gets FDA Orphan Drug Tag For Lung Infection
06:36am, Thursday, 19'th Aug 2021
The FDA has granted Orphan Drug Designation to Paratek Pharmaceuticals Inc's (NASDAQ: PRTK), Nuzyra (omadacycline) for infections caused by Nontuberculous Mycobacteria (NTM). The orphan drug des
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi
PRTK Stock Price Increases Over 4% Pre-Market: Why It Happened
07:43am, Tuesday, 10'th Aug 2021
The stock price of Paratek Pharmaceuticals Inc (NASDAQ: PRTK) increased by over 4% pre-market. This is why it happened.
Paratek Pharmaceuticals (PRTK) Q2 Earnings and Revenues Miss Estimates
07:13pm, Monday, 09'th Aug 2021
Paratek (PRTK) delivered earnings and revenue surprises of -31.03% and -3.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals: Q2 Earnings Insights
05:08pm, Monday, 09'th Aug 2021
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 137.74% over the past year to $0.20,
Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021
04:05pm, Monday, 09'th Aug 2021
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior Quarter
PRTK Stock Price Increases Over 10% Pre-Market: Why It Happened
07:18am, Thursday, 05'th Aug 2021
The stock price of Paratek Pharmaceuticals Inc (NASDAQ: PRTK) increased by over 10% pre-market. This is why it happened.
Paratek Stock Is Trading Higher As CDC Adds Nuzyra As Recommended Antibiotic For Plague Treatment
06:45am, Thursday, 05'th Aug 2021
The Center for Disease Control and Prevention (CDC) has added Paratek Pharmaceuticals Inc's (NASDAQ: PRTK) antibiotic Nuzyra (omadacycline) as an alternative agent for pre-exposure prophylaxis an
BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi
Paratek Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference 2021
04:30pm, Tuesday, 03'rd Aug 2021
BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi
